NUC discontinuation shows durable immune control in e antigen-negative hepatitis B

Discontinuation of long-term nucleos(t)ide analogues has the potential to induce durable immune control and functional cure in patients with e antigen-negative, or HBeAG, chronic hepatitis B, according to a presenter at The Digital International Liver Congress.In his presentation, Florian van Bömmel, from University Hospital Leizig in Germany, said that discontinuing nucleos(t)ide analogues (NUCs) can result in durable control of HBV replication in patients without HBeAg. He and his colleagues sought to assess this effect in a prospective, randomized trial called The Stop-NUC study.Read More

Share on facebook
Share on twitter
Share on linkedin